- Home
- NEHCW vs GNPX Comparison
NEHCW vs GNPX Comparison
Compare NEHCW & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEHCW
- GNPX
- Stock Information
- Founded
- NEHCW N/A
- GNPX 2009
- Country
- NEHCW United States
- GNPX United States
- Employees
- NEHCW N/A
- GNPX N/A
- Industry
- NEHCW Oil & Gas Production
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- NEHCW Energy
- GNPX Health Care
- Exchange
- NEHCW Nasdaq
- GNPX Nasdaq
- Market Cap
- NEHCW 836.3K
- GNPX 854.2K
- IPO Year
- NEHCW N/A
- GNPX 2018
- Fundamental
- Price
- NEHCW N/A
- GNPX $0.93
- Analyst Decision
- NEHCW
- GNPX Strong Buy
- Analyst Count
- NEHCW 0
- GNPX 1
- Target Price
- NEHCW N/A
- GNPX $10.00
- AVG Volume (30 Days)
- NEHCW N/A
- GNPX 854.6K
- Earning Date
- NEHCW N/A
- GNPX 11-13-2024
- Dividend Yield
- NEHCW N/A
- GNPX N/A
- EPS Growth
- NEHCW N/A
- GNPX N/A
- EPS
- NEHCW N/A
- GNPX N/A
- Revenue
- NEHCW N/A
- GNPX N/A
- Revenue This Year
- NEHCW N/A
- GNPX N/A
- Revenue Next Year
- NEHCW N/A
- GNPX N/A
- P/E Ratio
- NEHCW N/A
- GNPX N/A
- Revenue Growth
- NEHCW N/A
- GNPX N/A
- 52 Week Low
- NEHCW N/A
- GNPX $0.28
- 52 Week High
- NEHCW N/A
- GNPX $14.40
- Technical
- Relative Strength Index (RSI)
- NEHCW N/A
- GNPX 42.61
- Support Level
- NEHCW N/A
- GNPX $0.82
- Resistance Level
- NEHCW N/A
- GNPX $0.96
- Average True Range (ATR)
- NEHCW 0.00
- GNPX 0.10
- MACD
- NEHCW 0.00
- GNPX -0.01
- Stochastic Oscillator
- NEHCW 0.00
- GNPX 25.86
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.